Intravenous ferric carboxymaltose

DRUG5 trials

Sponsors

Nottingham University Hospitals NHS Trust, Hospital Aleman, Muhammad Aamir Latif, Erasmus Medical Center, University of Lagos

Conditions

AnaemiaAnemiaAortic Valve StenosisCardiovascular DiseasesColorectal NeoplasmHaematological Disorders Nutritional, Metabolic, Endocrine Pregnancy and Childbirth Maternal anaemia, preterm birth, maternal depression and low birth weightIron DeficiencyTAVI(Transcatheter Aortic Valve Implantation)

Phase 3

The use of iron administered as an infusion into a vein compared to the use of iron tablets taken by mouth for treating Nigerian women with iron deficiency anaemia during pregnancy (IVON trial)

Active, not recruitingPACTR202012843695208

University of LagosHaematological Disorders Nutritional, Metabolic, Endocrine Pregnancy and Childbirth Maternal anaemia, preterm birth, maternal depression and low birth weight

Start: 2021-01-04Target: 1056Updated: 2025-06-24

Phase 4

Intravenous Iron: Measuring Response in Anemic Surgical Patients

CompletedNCT02057471

Nottingham University Hospitals NHS TrustAnemia, Colorectal Neoplasm

Start: 2009-09-30End: 2012-03-31Updated: 2014-02-07

Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)

CompletedNCT02232906

Hospital AlemanAnaemia, Iron Deficiency

Start: 2011-03-31End: 2013-09-30Updated: 2014-09-05

Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation

RecruitingNCT07370688

Erasmus Medical CenterAortic Valve Stenosis, Cardiovascular Diseases, Iron Deficiency +1

Start: 2024-08-12End: 2028-07-01Target: 402Updated: 2026-01-27

Unknown Phase

Comparison of the Mean Change in Hemoglobin With Ferric Carboxymaltose and IV Iron Sucrose in Anemic Antenatal Patients

CompletedNCT07115121

Muhammad Aamir LatifAnemia

Start: 2025-02-02End: 2025-07-31Updated: 2025-09-05

Related Papers

Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status

PLoS ONE2015-04-3018 citations